Back to search

Michigan State University

Anti-tumor activity of novel RXR agonists

Abstract

dc:description

Retinoid X receptor (RXR) agonists bind to and activate the nuclear receptor RXR, thereby regulating gene transcription relevant to cellular proliferation, apoptosis, cell cycle, immunity, and numerous other biological processes. RXR agonists have been explored as treatments for cancer, metabolic disorders, and neurodegenerative diseases, and one RXR agonist, bexarotene, has been FDA approved for the treatment of cutaneous T cell lymphoma (CTCL). Bexarotene has also been tested in clinical trials for lung and metastatic breast cancer, wherein subsets of patients responded despite advanced disease. By modifying structures of known rexinoids, we can improve potency and toxicity. We have previously developed an in vitro screening paradigm that predicts activity in vivo and tested a series of novel rexinoids using this system of assays. This thesis project tested newly synthesized RXR agonists in preclinical mouse models of breast and lung cancer, diseases that cause significant morbidity and economic burden in the United States and worldwide. These novel compounds, V-125 and MSU 42011, are efficacious and well tolerated in the MMTV-Neu model of HER2+ breast cancer and the A/J model of non-small cell lung cancer. To generate mechanistic hypotheses for the anti-tumor efficacy of these novel compounds, RNA sequencing data from treated MMTV-Neu tumors is contained herein. Enrichment analyses of several RXR agonists depicts unique gene expression profiles, with unifying themes of immunomodulatory activity and modification of adhesion molecules and extracellular matrix components. This data and validation data provided direction for future mechanistic studies on the biological, immune modulatory, and anti-tumor effects of these compounds. By studying the mechanisms of these compounds, we may gain insight into how best to design future RXR agonists and how to utilize these compounds in human disease.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Reich, Lyndsey
Contributors dc:contributor
  • Liby, Karen
  • Rockwell, Cheryl
  • Gallo, Kathy
  • Doseff, Andrea
  • Bernard, Jamie

Subjects

dc:subject × 5

Rights

dc:rights
Statement dc:rights
  • In Copyright
Language dc:language
English

Identifiers

dc:identifier.*
Identifier
etd:50807
isbn:9798352954720
oclc:on1373601542
oclc:1373601542
umi:29399154
local:Reich_grad.msu_0128D_19478

Chain of custody

source
Harvested from
Michigan State University
Base URL
d.lib.msu.edu/oai
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Reich, Lyndsey. Anti-tumor activity of novel RXR agonists. 2022. https://doi.org/doi:10.25335/bbdq-8a24